Background: Acute pulmonary thromboembolism (APTE) is a life-threatening condition, often manifesting with chest pain, dyspnea, and increased cardiac biomarkers including cardiac troponin I (CTI) and D-dimer. Therefore, APTE is often misdiagnosed with classical non-ST elevation myocardial infarction (NSTEMI), resulting in unnecessary coronary interventions and a delay of therapy. Objectives: Our aim was to distinguish APTE from NSTEMI based on CTI and D-dimer levels. Methods: Complete clinical and laboratory data sets from APTE patients (n = 123) were compared with matched NSTEMI patients (n = 123) who presented with chest pain. The APTE diagnosis was confirmed by chest tomography, angiography, or radionuclide ventilation-perfusion scan, while NSTEMI was established by clinical symptoms, cardiac biomarkers, and coronary angiography. Clinical characteristics, CTI (initial and peak), and D-dimer levels at presentation were retrospectively analyzed. Results: The clinical characteristics were not different between APTE and NSTEMI patients. However, significantly lower initial CTI (0.2 ± 0.5 vs. 4.4 ± 9.5 ng/ml) and peak CTI (0.7 ± 2.7 vs. 17.1 ± 20.4 ng/ml), but higher initial D-dimer (9.8 ± 9.4 vs. 1.6 ± 3.6 ng/ml), distinguished APTE from NSTEMI. By receiver operating characteristic curve analysis, the cutoff values for initial CTI, peak CTI, and D-dimer were 0.25, 0.98, and 3.18 ng/ml, respectively. Conclusion: Patients with APTE exhibited lower initial and peak CTI but higher D-dimer levels than NSTEMI patients. Assessing cardiac biomarkers is useful for differentiating APTE from NSTEMI. Further large randomized biomarker studies are urgently needed to facilitate a better APTE diagnosis since clinical characteristics are not particularly helpful.

Keywords:
Acute pulmonary thromboembolism, Myocardial infarction, Cardiac troponin I, D-Dimer
1.
Becattini C, Vedovati MC, Agnelli G: Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007;116:427-433.
2.
Calwin Davidsingh S, Srinivasan N, Balaji P, Kalaichelvan U, Mullasari AS: Study of clinical profile and management of patients with pulmonary embolism - single center study. Indian Heart J 2014;66:197-202.
3.
Gul EE, Nikus KC, Erdogan HI, Ozdemir K: Differential diagnostic dilemma between pulmonary embolism and acute coronary syndrome. J Arrhythm 2016;32:160-161.
4.
Mehta NJ, Jani K, Khan IA: Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003;145:821-825.
5.
Vuilleumier N, Limacher A, Mean M, Choffat J, Lescuyer P, Bounameaux H, Aujesky D, Righini M: Cardiac biomarkers and clinical scores for risk stratification in elderly patients with non-high-risk pulmonary embolism. J Intern Med 2015;277:707-716.
6.
Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman M, Humbert M, et al: 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-3080.
7.
Raja AS, Greenberg JO, Qaseem A, Denberg TD, Fitterman N, Schuur JD; Clinical Guidelines Committee of the American College of Physicians: Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2015;163:701-711.
8.
Huisman MV, Klok FA: How I diagnose acute pulmonary embolism. Blood 2013;121:4443-4448.
9.
Coen Herak D, Milos M, Zadro R: Evaluation of the Innovance D-DIMER analytical performance. Clin Chem Lab Med 2009;47:945-951.
10.
Park SJ, Chi HS, Chun SH, Jang S, Park CJ: Evaluation of performance including influence by interfering substances of the Innovance D-dimer assay on the Sysmex coagulation analyzer. Ann Clin Lab Sci 2011;41:20-24.
11.
Riley RS, Gilbert AR, Dalton JB, Pai S, McPherson RA: Widely used types and clinical applications of D-dimer assay. Lab Med 2016;47:90-102.
12.
Torpy JM, Burke AE, Glass RM: Acute coronary syndromes. JAMA 2010;303:90.
13.
Scirica BM: Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol 2010;55:1403-1415.
14.
Wolf SJ, McCubbin TR, Feldhaus KM, Faragher JP, Adcock DM: Prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism. Ann Emerg Med 2004;44:503-510.
15.
Dieter RS, Ernst E, Ende DJ, Stein JH: Diagnostic utility of cardiac troponin-I levels in patients with suspected pulmonary embolism. Angiology 2002;53:583-585.
16.
Adam SS, Key NS, Greenberg CS: D-Dimer antigen: current concepts and future prospects. Blood 2009;113:2878-2887.
17.
Cohen AT, Spiro TE, Spyropoulos AC, Desanctis YH, Homering M, Buller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Tapson VF, Burton P, Group MS: D-Dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 2014;12:479-487.
18.
Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, Heckbert SR: Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003;101:1243-1248.
19.
Teismann NA, Cheung PT, Frazee B: Is the ordering of imaging for suspected venous thromboembolism consistent with D-dimer result? Ann Emerg Med 2009;54:442-446.
20.
Linkins LA, Bates SM, Ginsberg JS, Kearon C: Use of different D-dimer levels to exclude venous thromboembolism depending on clinical pretest probability. J Thromb Haemost 2004;2:1256-1260.
21.
Kim YJ, Im S, Jang YJ, Park SY, Sohn DG, Park GY: Diagnostic value of elevated D-dimer level in venous thromboembolism in patients with acute or subacute brain lesions. Ann Rehab Med 2015;39:1002-1010.
22.
Kristoffersen AH, Ajzner E, Rogic D, Sozmen EY, Carraro P, Faria AP, Watine J, Meijer P, Sandberg S: Is D-dimer used according to clinical algorithms in the diagnostic work-up of patients with suspicion of venous thromboembolism? A study in six European countries. Thromb Res 2016;142:1-7.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.